DNA2.0 is the largest gene synthesis provider in the US, and a pioneer of several novel applications for synthetic genes including protein engineering, codon optimization and RNAi resistant genes.

As part of Adimab’s ongoing effort to efficiently integrate all aspects of therapeutic antibody discovery, the company has entered into a strategic relationship with DNA2.0.

Adimab is working closely with DNA2.0 to optimize all aspects of antibody library design, antibody maturation and antibody presentation. In addition, we are systematically optimizing the expression of antibody frameworks in yeast to improve the production and formulation of therapeutic antibodies. Our relationship with DNA2.0 allows us to apply Adimab’s computational biology capabilities to the interpretation of large-scale antibody library screens and rapidly integrate them into the Adimab discovery, maturation and bio-manufacturing platform.

> DNA2.0